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conjugate vaccine in patients with rheumatoid
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Introduction: The objective of the study was to investigate the impact of newer biologic treatments including
rituximab, abatacept and tocilizumab on antibody response following pneumococcal vaccination using a 7-valent
conjugate vaccine in patients with established rheumatoid arthritis (RA).
Methods: Patients with RA receiving rituximab, abatacept or tocilizumab as monotherapy or combined with
methotrexate (MTX) participated in the study. Specific IgG antibodies against 23F and 6B serotypes were measured
at vaccination and 4 to 6 weeks after vaccination using standardised ELISA. Geometric mean antibody levels (GML)
were calculated. Antibody response (AR) was defined as the ratio between post- and pre-vaccination antibody levels
and a positive antibody response (posAR) was AR ≥2.
Results: In total, 88 patients were enrolled in the study. Of 55 patients treated with rituximab, 26 (46%) were on
concomitant MTX. Of patients receiving abatacept (n = 17) and tocilizumab (n = 16) biologic treatment was given in
combination with MTX in 13 (76%) and 9 (56%) patients, respectively. Patients treated with rituximab had
significantly lower AR compared to those on tocilizumab, as well as compared to previously reported RA patients
on MTX and controls (spondylarthropathy patients treated with NSAIDs and/or analgesics). In total, 10.3% of
patients on rituximab monotherapy and no patient on rituximab +MTX had posAR for both serotypes. For
abatacept and tocilizumab the corresponding figures were 17.6% and 50%.
Conclusion: In this cohort of patients with established RA, treatment with rituximab and abatacept was associated
with diminished antibody response but this was most pronounced for rituximab. Pneumococcal conjugate vaccine
administrated during ongoing tocilizumab treatment seems to be associated with sufficient antibody response.
Pneumococcal vaccination should preferably be encouraged before initiation of rituximab or abatacept treatment.
Trial registration: NCT00828997 and EudraCT EU 2007-006539-29.Introduction
A population-based surveillance over 4 years after licen-
sure of the 7-valent pneumococcal conjugate vaccine (Pre-
venar, PCV7) for children in the USA showed a significant
decrease of invasive pneumococcal disease (IPD) among
adults 50 years and older, but also an increase of IPD
caused by serotypes not included in the vaccine [1]. A new* Correspondence: meliha.c_kapetanovic@med.lu.se
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distribution, and reproduction in any mediumpneumococcal conjugate vaccine containing 13 different
pneumococcal capsular antigens 1, 3, 4, 5, 6A, 6B, 7F, 9V,
14, 18C, 19A, 19F and 23F has recently been approved
by the authorities in USA and Europe for primary and
secondary immunization in children. The Centre for
Disease Control and Prevention (CDC) Advisory Com-
mittee on Immunization Practices recently updated
recommendations for pneumococcal vaccination, and
these include immunization with a dose of 13-valent
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term systemic corticosteroids [2].
Pneumococcal vaccination is strongly encouraged by the
European League Against Rheumatism (EULAR) for pa-
tients with inflammatory rheumatic diseases [3]. Data on
the benefit of pneumococcal conjugate vaccine in immuno-
suppressed patients with rheumatic disease are scarce. Our
group has reported on antibody response following vac-
cination with PCV7 in patients with rheumatoid arthritis
(RA) and spondylarthropathy (SpA) including ankylosing
spondylitis and psoriatic arthritis treated with different
anti-inflammatory remedies. Methotrexate (MTX), but not
anti-TNF drugs, was associated with decreased antibody
response [4].
Along with anti-TNF drugs newer treatment modalities
have been available for treatment of RA in the last decade.
These include a chimeric anti-CD20 monoclonal anti-
body rituximab, a selective T-cell co-stimulation modulator
(abatacept) and a humanized anti-IL-6 receptor monoclo-
nal antibody (tocilizumab). Studies on antibody response
following pneumococcal vaccination in patients with estab-
lished arthritis receiving these treatments are scarce.
The present work is an extension of a report on anti-
body response following pneumococcal vaccination using
7-valent conjugate vaccine in arthritis patients treated with
TNF-inhibitors [4]. The objective of the study was to in-
vestigate the immunogenicity and tolerability of the 7-
valent pneumococcal conjugate vaccine in patients with
established RA treated with biologic remedies other than
TNF-inhibitors.
Methods
RA patients regularly monitored at the Department of
Rheumatology, Skåne University Hospital in Lund and
Malmö, Sweden, were invited to participate in the study as
previously described [4]. The Regional Ethic Review Board
at Lund University approved the study (file number 97/
2007). The study was conducted as an investigator-driven
clinical trial, registered online at EudraCT EU 2007-
006539-29 [5] and at NCT00828997, and approved by the
Swedish Medical Products Agency (MPA; file number
151: 2007/88047). Informed written consent was obtained
from all subjects before study entry. Initially, 505 patients
with RA or spondylarthropathy participated in the study
[4]. In the extended part of the study, RA patients receiv-
ing treatment with biologic remedies other than TNF an-
tagonists were offered vaccination. Only RA patients being
on the biologic drug for at least 4 weeks were eligible for
the study. The vast majority of these patients had previ-
ously been treated with one or more anti-TNF remedies
and the number of previously given biologic treatments
was calculated. All patients received one dose (0.5 ml) of
heptavalent pneumococcal conjugate vaccine (Prevenar)
intramuscularly. Blood samples were drawn at vaccinationand 4 to 6 weeks thereafter. Immunoglobulin (Ig)G anti-
bodies specific for Streptococcus pneumoniae capsular
polysaccharides 6B and 23F were measured using ELISA
as previously described [6]. Briefly, ELISA plates were
coated with the polysaccharides 23F or 6B. Dilutions
of human sera absorbed with pneumococcal cell wall
polysaccharide were then added to the ELISA plates. A
reference serum was included on all plates. The serotype-
specific antibodies for 23F and 6B were detected using
alkaline phosphatase-conjugated goat anti-human IgG
(-chain specific) F(ab’)2 fragments, followed by addition of
the substrate p-nitrophenyl phosphate. The optical density
at 405 nm was measured with an ELISA plate reader. The
optical density of the colored end-product is proportional
to the amount of specific antibodies present in the serum.
The lower limit of detection was 0.02 mg/L for serotype
6B and 0.01 mg/L for 23F.
Geometric mean antibody levels (GML) prior to and
after vaccination were calculated from log-transformed
values and compared to previously reported GML of
MTX-treated patients and controls (SpA patients on
non-steroidal anti-inflmmatory drugs (NSAIDs)/analge-
sics). Antibody response (AR) was defined as the ratio
between post- and prevaccination antibody levels and a
positive AR (posAR) as at least two-fold increase in AR
as described [4].
Study population
In total, 88 patients (74% women) treated with biologic
remedies other than TNF inhibitors participated in the
study. Mean (SD; range) age and disease duration in the
whole group was 60.2 (2.0; 41.0 to 85.0) and 16.0 (2.0; 2.0
to 46.0) years, respectively. Mean Disease Activity Score
(DAS) (SD) and Health Assessment Questionnaire (HAQ)
score (SD) at vaccination was 4.5 (0.2) and 1.3 (0.1),
respectively. Of these 88 patients, 89% patients were
rheumatoid factor (RF)-positive and 82% were anti-cyclic
citrullinated peptide (CCP)-positive. All patients fulfilled
the American College of Rheumatologists (ACR) classifi-
cation criteria for RA [7]. Treatment was as follows: 55 pa-
tients were treated with rituximab, 17 with abatacept and
16 with tocilizumab. Biological treatment was given as
monotherapy to 40 of 88 (44.5%). The remaining 48 pa-
tients received concomitant MTX and of these, 3 were
also treated with sulphasalazine and 2 with hydroxychlor-
oquine. Mean number (range) of previous biologics was
1.2 (0.0 to 4.0), 2.4 (0.0 to 5.0) and 2.0 (0.0 to 6.0) in pa-
tients on rituximab, abatacept and tocilizumab, respect-
ively. Rituximab-treated patients had lower IgG and IgM
levels compared to those with the other two treatments.
Statistical analysis
Non-parametric tests were generally used. Differences in
AR between two treatment groups at the time were
Crnkic Kapetanovic et al. Arthritis Research & Therapy 2013, 15:R171 Page 3 of 9
http://arthritis-research.com/content/15/5/R171calculated using the Mann-Whitney U-test. The associ-
ation between age, disease duration, DAS, HAQ score,
ongoing MTX dose, ongoing prednisolone dose and
IgM/IgG levels at vaccination and positive immune re-
sponse (posAR; yes/no) was analyzed using the Mann-
Whitney U-test. The Chi-squared test was applied to
calculate the influence of gender, RF/anti-CCP positivity
(yes/no), concomitant MTX (yes/no), concomitant pred-
nisolone (yes/no) and for each biologic treatment at
vaccination on posAR (yes/no). Possible predictors of
posAR were explored in multivariate binary logistic
regression model adjusted for significantly different
baseline demographic and disease characteristics. Be-
cause age and disease duration correlated significantly
(Spearman correlation factor >0.3; P <0.001), as well as
28-joint DAS (DAS28) and HAQ score (Spearman
correlation factor >0.6; P <0.001), only disease duration
and DAS28 could be included in the same regression
analysis. The following variables were included in the
final model: disease duration, gender, DAS, concomitant
MTX, concomitant prednisolone dose and rituximab
treatment at vaccination. Due to the limited number of
patients, the impact of abatacept and tocilizumab treat-
ment on posAR could not be analyzed in a multivariate
logistic regression model.
Results
Demographic and disease characteristics at vaccination,
and GML of pre- and postvaccination antibody levels for
serotype 6B and 23F, for each separate serotype in RA
patients treated with rituximab, abatacept and toci-
lizumab are summarized in Table 1. Previously reported,
corresponding data in RA patients on MTX and controls
(SpA patients on NSAIDs and/or analgesics) are also
shown.
Figure 1 shows box plots with AR for serotype 6B and
23F in the different treatment groups.
Rituximab
At vaccination mean rituximab treatment time was 1.3
years. Of 55 patients treated with rituximab, 26 (46%)
were on concomitant MTX. The differences in AR, that
is, post-/prevaccination antibody levels between patients
on rituximab as monotherapy or rituximab + MTX were
not significant for any of the serotypes. Rituximab-
treated patients as a group had significantly lower AR
for each serotype compared to RA patients on MTX, RA
on tocilizumab, and controls (Figure 1). Compared to
abatacept, rituximab-treated patients had lower AR for
each serotype but differences were not significant.
Rituximab-treated patients as a group had impaired
posAR for both serotypes tested compared to MTX,
tocilizumab and controls (Figure 2) but not abatacept-
treated patients with RA (P = 0.112). More patientstreated with rituximab as monotherapy were responders
for each separate serotype but the differences were not
significant. However, no patients on rituximab + MTX
were responders for both serotypes together (Figure 2).
All patients treated with rituximab (n = 55) had re-
ceived a minimum of two treatments and vaccination
was administered at least 4 weeks after the first treat-
ment. Mean (range) time between last treatment and
vaccination was 86 (0 to 894) days. Of 55 patients 37
(67.3%) were vaccinated within 3 months and the major-
ity of patients (n = 49; 89.1%) within 6 months following
the last rituximab infusion. There were no statistically
significant differences in antibody responses between pa-
tients vaccinated within ≤180 days compared to those
receiving vaccination >180 days after the last rituximab
treatment.
Abatacept
Of 17 patients treated with abatacept, 13 patients (76%)
received concomitant MTX. Vaccination was adminis-
trated on average 8 (0 to 26) days after infusion. Mean
abatacept treatment time at vaccination was 0.8 years.
Demographic and disease characteristics did not differ sig-
nificantly between patients receiving abatacept as mono-
therapy or combined with MTX. All patients treated with
abatacept were analyzed as a group. Compared to MTX-
treated patients with RA, abatacept-treated patients had
better posAR for serotype 6B but worse for serotype 23F.
The proportion of patients on abatacept with posAR for
both serotypes was lower compared to RA patients on
MTX but the differences were not significant. A signifi-
cantly smaller proportion of patients on abatacept had
posAR for both serotypes compared to those on toci-
lizumab and controls (Figure 2).
Tocilizumab
Of 16 patients on tocilizumab, 9 (54%) had concomitant
MTX. Vaccination was performed on average (range) 7
(0 to 34) days after infusion. Mean tocilizumab treat-
ment time at vaccination was 0.3 years. Regardless of
MTX treatment, tocilizumab-treated patients as a group
had lower pre- and postvaccination GML levels for both
serotypes compared to controls. However, the immune
response for each serotype, and posAR for 6B and 23F
both separately and together were as good as those of
controls. Tocilizumab-treated patients had significantly
better posAR compared to rituximab-, abatacept- or
MTX-treated patients with RA (Figure 2).
Predictor analysis
Possible predictors of posAR for both serotypes were stud-
ied using a logistic regression model with adjustment for
differences in disease duration, gender, DAS, concomitant
MTX and prednisolone at vaccination (Table 2). Both
Table 1 Demographic and disease characteristics at vaccination, and prevaccination- and postvaccination GML in RA
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Female gender, % 72% 62% 88% 81% 79% 45%
























HAQ, 0 to 3 1.2 (0.8) 1.1 (0.6) 1.4 (0.6) 1.5 (0.7) 0.7 (0.6) 0.5 (0.5)
DAS, 0 to 7 3.9 (1.2) 3.9 (1.1) 4.9 (1.2) 3.6 (1.7) 3.7 (1.2) 3.0 (1.1)
Ongoing MTX, yes, % —— 100% 76% 56% 100% ——
MTX mg/week, mean —— 17.2 15.6 14.7 16.4 ——
Ongoing prednisolone,yes, % 55.2% 65.4% 70.0% 53.3% 31.3% 6.2%
Prednisolone, mg/week, mean 30.9 35.4 32.7 27.5 14.0% 2.2
CRP mg/L, mean 15.8 6.4 9.7 3.9 8.9 7.7
TJC28, mean (range) 3.5 (0 to 23) 4.7 (0 to 19) 8.2 (0 to 20) 7.6 (0 to 28) 2.8 (0 to 12) 1.9 (0 to 18)
SJC, mean (range) 3.4 (0 to 15) 3.9 (0 to 13) 4.8 (0 to 12) 5.1 (0 to 25) 2.0 (0 to 11) 0.4 (0 to 5)
RF-positive, % 93% 89% 88% 81% 78% NA
Anti-CCP-positive, % 86% 92% 82% 63% 75% NA
Smoker, % 14% 31% 19% 14% 19% 12%
IgG at vaccination, g/L, mean (SD) 8.2 (2.9) 8.0 (2) 9.1 (1.9) 8.7 (2.6) 9.7 (2.5) 9.9 (2.1)
IgM at vaccination, g/L, mean (SD) 0.8 (0.7) 0.9 (0.5) 1.3 (0.7) 1.1 (0.5) 1.1 (0.6) 1.0 (0.6)
IgA at vaccination, g/L, mean (SD) 2.3 (1.3) 2.4 (0.9) 2.9 (1.3) 2.5 (0.9) 2.5 (1.1) 2.5 (1.1)
Pneumococcal vaccine previously, % 24.1% 23.1% 11.8% 6.3% 10.6% 1.2%
Last biologic treatment before
vaccination, days, mean (range)
71 (0 to 501) 102 (0 to 894) 8 (0 to 26) 7 (0 to 34) NA NA
Prevaccination antibody levels for 6B,
mg/L, GML (95% CI)
0.3 (0.2-0.6) 0.4 (0.2, 0.8) 0.6 (0.3, 1.4) 0.4 (1.0, 1) 2.0 (1.4, 2.8) 2.9 (2.1, 4.0)
Postvaccination antibody levels for 6B,
mg/L, GML (95% CI)
0.4 (0.2-0.8) 0.4 (0.2, 0.8) 1.1 (0.4, 2.7) 1.7 (0.5, 5.8) 3.5 (2.5, 4.9) 9.5 (6.7, 13.6)
Prevaccination antibody levels for 23F,
mg/L, GML (95% CI)
0.2 (0.1, 0.4) 0.3 (0.1, 0.5) 0.4 (0.2, 0.9) 0.2 (0.1, 0.5) 0.7 (0.5, 1.1) 0.97 (0.7, 1.4)
Postvaccination antibody levels for 23F,
mg/L, GML (95% CI)
0.3 (0.2, 0.6) 0.4 (0.2, 0.8) 1.1 (0.6, 2.3) 2.2 (0.9-5.3) 1.9 (1.4, 2.6) 6.4 (4.5, 9.1)
Controls were patients with spondyloarthropathy on non-steroidal anti-inflammatory drugs/analgesics. GML, geometric mean antibody levels; RA, rheumatoid
arthritis; MXT, methotrexate; HAQ, health assessment questionnaire; DAS, disease activity score; TJC, tender joint count; SJC, swollen joint count; RF, rheumatoid
factor; anti-CCP, anti-cyclic citrullinated peptide antibody; NA, not applicable.
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serotypes (P = 0.033 and 0.044, respectively). Patients with
longer disease duration (P = 0.016) and higher disease ac-
tivity (P = 0.028) showed decreased response (P = 0.07),
but no significant effect of sex or concomitant prednisol-
one dose was observed.
As previously reported, pneumococcal conjugate vac-
cine was generally well-tolerated and no severe adverse
event was reported within 4 to 6 weeks after vaccination
among patients receiving biologic treatment other than
anti-TNF. Pain at the injection site was the most com-
monly reported side effect, followed by headache, feverand fatigue for a few days. One case of uncomplicated
lower urinary tract infection requiring treatment with
antibiotics was reported in a patient on rituximab. One
patient suffered from significantly more joint pain but
the number of swollen joins was unchanged compared
to that before vaccination. No increased activity in RA
disease or onset of other immunological disease was
observed.
Discussion
Here we report a study on AR following pneumococcal
vaccination using pneumococcal conjugate vaccine in
Figure 1 Box plots show 5th/95th percentiles of antibody response, that is, ratio of postvaccination/prevaccination antibody levels for 6B
and 23F in different treatment groups. Statistically significant differences in antibody response for each serotype when two different treatment groups
were compared (Mann-Whitney U-test) are indicated. MTX, methotrexate; Spondylart, spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug.
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TNF inhibitors.
In this cohort of patients with established RA, who
were previously exposed to up to six other biologicdrugs, ongoing treatment with abatacept and rituximab
impaired the antibody response. The negative impact
was most pronounced in rituximab-treated patients and
additionally diminished when concomitant MTX was
Figure 2 Percentage of patients with positive immune response defined as at least two-fold increase in prevaccination antibody levels
for serotype 6B, 23F and both 6B and 23F in different treatment groups. Statistically significant differences in positive immune response for
both 23F and 6B serotypes when two different treatment groups were compared to each other (Chi-squared test) are indicated. MTX,
methotrexate; SpA, spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug.
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of arthritis patients not receiving immunosuppressive
drugs.
T-cell-dependent mechanisms are important for AR
following immunization with protein antigen [8]. Antigen-
presenting cells, including B-cells, are required for presen-
tation of protein antigens to naive T-cells which thereby
stimulate secretion of different cytokines and activate B-
cells to differentiate into antigen-specific Ig-producingplasma cells. A lack of mature B-cells results in a lower
amount of plasma cells and as a consequence lower
production of serotype-specific antibodies [8]. As pneu-
mococcal conjugate vaccine consists of capsular polysac-
charides conjugated to a protein carrier, this could be one
possible mechanism for reduced AR following B-cell de-
pletion therapy using rituximab. Our results are in line
with previously reported diminished IgG response fol-
lowing immunization with protein antigen (influenza
Table 2 Predictors of positive immune response for both
serotypes (23F + 6B) using multivariate logistic regression
analysis
P-value Odds ratio 95% CI
Sex, male/female 0.269 0.34 0.05, 0.31
Disease duration, years 0.016 0.90 0.82, 0.98
DAS28 0.028 0.53 0.30, 0.93
MTX at vaccination, yes/no 0.044 0.13 0.02, 0.94
Prednisolone at vaccination, mg/week 0.118 0.02 1.00, 1.04
Rituximab at vaccination, yes/no 0.033 0.06 0.01, 0.80
DAS28, 28-joint Disease Activity Score; MTX, methotrexate.
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ized controlled study investigating AR following pneumo-
coccal vaccination using 23-valent polysaccharide vaccine
also showed impaired response in RA patients on rituxi-
mab [10].
Our findings of modestly decreased levels of circulating
IgG, IgM and IgA among rituximab treated patients are in
line with those previously reported in RA patients after
subsequent rituximab courses [11]. Indeed, patients par-
ticipating in this study had received at least two rituximab
treatments at the time of vaccination and a substantial
number was treated with subsequent courses every 6
months. Thus, low levels of serotype-specific antibodies
already present before vaccination might be explained by
universal depletion of B-memory cells. In contrast to re-
sults from van Assen et al. no significant correlation be-
tween timing of vaccination in relation to administration
of rituximab was found in our study [9]. Long-lasting de-
pletion of the whole pool of B-memory cells and not only
circulating B-cells caused by repeated rituximab treat-
ments might explain the diverging results.
The abatacept-treated RA patients had decreased anti-
body response compared to controls and tocilizumab-
treated patients with RA. Abatacept attenuates activation
of naive T-cells by blocking the interaction between CD80/
86 and CD28, a co-stimulation signal required for full T-
cell activation. RA patients have many CD28-null T-cells.
In addition, abatacept (CTLA-4Ig) also prevents CTLA-4
binding to its ligand [12]. This may result in inhibition of
T-cell proliferation and subsequently inadequate stimula-
tion of B-cells. Diminished B-cell immunological response
might be a consequence of inadequate stimulation needed
for their differentiation into plasma cells. Results from our
study are in accordance with another study investigating
AR following pneumococcal vaccination after administra-
tion of abatacept to healthy adults, where a diminished AR
in subjects immunized after administration of one dose
of abatacept was reported [12]. The negative impact of
abatacept on AR was significantly less prominent com-
pared to that of rituximab. Despite the limited number of
abatacept-treated patients participating in the study ourresults suggest that the inhibition of the secondary co-
stimulation signal does not appear to have a critical role in
antibody production following conjugated polysaccharide-
protein antigen challenge. On the other hand, AR after in-
fluenza vaccination in RA patients on abatacept was found
to be severely impaired [13].
In contrast to the effects of rituximab and abatacept on
AR, we previously reported that the response in arthritis
patients on anti-TNF treatments was not significantly dif-
ferent from that in arthritis patients not receiving im-
munosuppressive drugs immunized with pneumococcal
conjugate vaccine, or healthy individuals immunized with
polysaccharide vaccine [4,14]. These results are in line
with earlier experimental data published by Cope et al.
showing that anti-TNF treatment in RA did not impair,
but enhanced T-cell responses to polypeptide antigen to-
wards normal response [15].
IL-6 plays an important role in differentiation of B-
cells into antibody producing plasma cells [16]. Thus
blockade of IL-6 would be expected to diminish anti-
body production. However, antibody response after in-
fluenza vaccination was not hampered in patients with
RA treated with tocilizumab [17]. Antibody response
among patients treated with tocilizumab in our study,
immunized after an average of 7 days following the last
treatment course, was similar to controls (SpA patients
not treated with immunosuppressive drugs). Along with
results from Mori et al. our results suggest that IL-6 is
not essential for antibody production after conjugated
polysaccharide-protein challenge, which is consistent
with previously reported experimental data [17,18]. IL-6
may still have an impact on IgG production by influen-
cing IgG subclasses differently, but this is not possible to
assess from our results.
Ongoing rituximab treatment was identified as a pre-
dictor of insufficient AR. Patients with higher disease
activity and longer disease duration had decreased re-
sponse but no effect of age and sex was observed. The
majority of patients enrolled in the present study were
women and differences in age between treatment groups
were rather small. Thus the impact of age and sex might
be difficult to discern.
MTX was identified as a predictor of impaired positive
AR in a multivariate logistic regression model, which is
in accordance with our previous reports including arth-
ritis patients treated by anti-TNF remedies [4,14]. The
number of patients treated with abatacept and toci-
lizumab was limited in the present study, precluding the
separate analysis of effect of MTX on AR in these
groups. Among rituximab-treated patients those receiv-
ing concomitant MTX had a lower antibody response,
which also confirms our previous results [4,14].
The AR is a surrogate marker of protection against in-
fection. The correlation between certain antibody levels
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including pneumococcal vaccine [19]. However, results
from the present study do not exclude the possibility
that rituximab- and abatacept-treated patients would
mount the appropriate immune response when exposed
to Streptococcus pneumoniae.
In addition, antibody response to two of seven sero-
types included in the vaccine was studied. Serotypes
6B and 23F are shown to be associated with invasive
pneumococcal disease in Sweden, which was the reason
for choosing these serotypes [20]. Although response to
other serotypes may differ, we hypothesize that the ef-
fects of different biologic treatments would influence AR
to other serotypes in a similar fashion.
The disadvantage of the present study is the small sam-
ple size in groups treated with abatacept and tocilizumab
compared to RA patients on MTX, and controls. Further
research including larger groups of patients on newer bio-
logics given as monotherapy and in combination with
conventional disease-modifying anti-rheumatic drugs is
needed.
Conclusions
In this cohort of patients with established RA, treatment
with rituximab and abatacept was associated with im-
paired antibody response following protein-polysaccharide
antigen challenge, but the impact of rituximab was more
substantial. The IL-6 receptor blockade did not hamper
antibody response in these patients. Pneumococcal vaccin-
ation should preferably be encouraged before initiation of
rituximab or abatacept treatment. Pneumococcal vaccine
administered during ongoing anti-IL-6 receptor treatment
seems to be associated with sufficient immune response in
patients with RA.
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